<p>Sofosbuvir is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.<br />
<br />
Sofosbuvir efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.<br />
<br />
The following points should be considered when initiating treatment with Sofosbuvir:</p>

<ul>
	<li>Monotherapy of Sofosbuvir is not recommended for treatment of CHC.</li>
	<li>Treatment regimen and duration are dependent on both viral genotype and patient population.</li>
	<li>Treatment response varies based on baseline host and viral factor.</li>
</ul>